Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jafron Biomedical Co.,Ltd. (300529.SZ)
CNY17.07
+0.52 (+3.14%)
CN SHZ Healthcare Medical - Specialties
Address
No. 98 Technology Six Road 519085
Zhuhai, SC, CN
Zhuhai, SC, CN
CEO
Fan Dong
Website
jafroninternational.com
IPO
2016-08-02
ISIN CNE100002995
Description
Jafron Biomedical Co.,Ltd. engages in the research and development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket, PGA absorbable suture with needle, syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY17.07
+0.52 (+3.14%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.42
Float Shares
590.26M
Free Float %
76.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.73% | -3.14% | -4.46% | -8.36% | -10.53% | -7.52% | -16.67% | -37.23% | -78.95% | +122.37% | +122.37% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
17.07
DCF (Unlevered)
19.16
+12.3%
DCF (Levered)
25.30
+48.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
6.69
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%-24.9% Q1'26: +2.3% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-34.3% Q1'26: +20.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+25.4% Q1'26: +38.1% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+35.2% ★ Q1'26: +47.5% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+50.2% ★ Q1'26: +39.1% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+0.7% Q1'26: -3.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.22× ★ Q1'26: 1.05× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
543.64M
est: 661.00M (-17.8%)
|
718.49M
est: 825.00M (-12.9%)
|
1.02B
est: 1.02B (+0.0%)
|
1.43B
est: 1.43B (+0.3%)
|
1.95B
est: 1.95B (-0.2%)
|
2.68B
est: 2.66B (+0.6%)
|
2.49B
est: 3.15B (-20.9%)
|
1.92B
est: 2.41B (-20.1%)
|
2.68B
est: 3.00B (-10.8%)
|
2.01B
est: 2.16B (-6.7%)
|
2.16B
2.16B – 2.16B
+0.1% YoY
|
2.33B
2.33B – 2.33B
+8.1% YoY
|
2.54B
2.46B – 2.62B
+9.0% YoY
|
| EBITDA |
240.40M
est: 283.32M (-15.1%)
|
310.71M
est: 353.61M (-12.1%)
|
431.19M
est: 435.70M (-1.0%)
|
634.29M
est: 611.85M (+3.7%)
|
1.00B
est: 837.95M (+19.6%)
|
1.37B
est: 1.14B (+20.5%)
|
995.72M
est: 1.35B (-26.3%)
|
573.43M
est: 981.48M (-41.6%)
|
1.12B
est: 1.22B (-8.5%)
|
825.76M
est: 879.56M (-6.1%)
|
880.15M
880.15M – 880.15M
+0.1% YoY
|
951.13M
951.13M – 951.13M
+8.1% YoY
|
1.04B
1.01B – 1.07B
+9.0% YoY
|
| EBIT |
225.78M
est: 262.50M (-14.0%)
|
294.51M
est: 327.63M (-10.1%)
|
409.40M
est: 403.68M (+1.4%)
|
604.50M
est: 566.90M (+6.6%)
|
965.51M
est: 776.39M (+24.4%)
|
1.32B
est: 1.06B (+25.4%)
|
926.66M
est: 1.25B (-25.9%)
|
482.98M
est: 886.76M (-45.5%)
|
997.98M
est: 1.11B (-9.7%)
|
708.59M
est: 794.68M (-10.8%)
|
795.20M
795.20M – 795.20M
+0.1% YoY
|
859.34M
859.34M – 859.34M
+8.1% YoY
|
936.60M
908.21M – 964.99M
+9.0% YoY
|
| Net Income |
202.12M
est: 254.17M (-20.5%)
|
284.41M
est: 318.72M (-10.8%)
|
401.98M
est: 383.27M (+4.9%)
|
570.82M
est: 539.80M (+5.7%)
|
875.24M
est: 815.08M (+7.4%)
|
1.20B
est: 1.13B (+6.2%)
|
889.56M
est: 1.19B (-25.1%)
|
436.49M
est: 688.88M (-36.6%)
|
820.20M
est: 1.05B (-21.9%)
|
532.82M
est: 532.82M (+0.0%)
|
629.35M
629.35M – 629.35M
+18.1% YoY
|
698.85M
698.85M – 698.85M
+11.0% YoY
|
783.79M
783.79M – 783.79M
+12.2% YoY
|
| SGA |
218.73M
est: 218.06M (+0.3%)
|
276.83M
est: 272.16M (+1.7%)
|
386.34M
est: 335.33M (+15.2%)
|
537.15M
est: 470.91M (+14.1%)
|
587.45M
est: 644.93M (-8.9%)
|
729.46M
est: 877.17M (-16.8%)
|
838.78M
est: 1.04B (-19.3%)
|
787.89M
est: 800.19M (-1.5%)
|
881.19M
est: 997.81M (-11.7%)
|
633.15M
est: 717.09M (-11.7%)
|
717.57M
717.57M – 717.57M
+0.1% YoY
|
775.44M
775.44M – 775.44M
+8.1% YoY
|
845.16M
819.54M – 870.78M
+9.0% YoY
|
| EPS |
0.27
est: 0.33 (-17.5%)
|
0.36
est: 0.42 (-13.4%)
|
0.51
est: 0.50 (+2.0%)
|
0.72
est: 0.70 (+2.2%)
|
1.10
est: 1.06 (+3.4%)
|
1.49
est: 1.47 (+1.4%)
|
1.12
est: 1.55 (-27.7%)
|
0.55
est: 0.89 (-38.3%)
|
1.05
est: 1.36 (-22.8%)
|
0.69
est: 0.69 (+0.0%)
|
0.82
0.82 – 0.82
+18.1% YoY
|
0.91
0.91 – 0.91
+11.0% YoY
|
1.02
1.02 – 1.02
+12.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
109.09M
OE per share TTM
0.14
Owner's Yield
0.76%
Maintenance CapEx ratio
89.73%
Maint CapEx / Avg PPE
66.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 34 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 5.1K | 0.15% |
| 2 | Franklin FTSE China ETF FLCH | 0.01% | 15.6K | 0.19% |
| 3 | Franklin FTSE China UCITS ETF FLXC.L | 0.00% | 72.4K | 0.19% |
| 4 | State Street SPDR S&P China ETF GXC | 0.00% | 15.3K | 0.59% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 125.4K | 0.39% |
| 6 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 160.0K | 0.06% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 120.0K | 0.29% |
| 8 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 15.9K | 0.48% |
| 9 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 35.9K | 0.26% |
| 10 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.77M | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
253.3K
Shares Outstanding
772.69M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aijun Wu | Vice President | — | male |
| Cong Huang | Board Secretary | — | female |
| De Zhi Li | Vice President | — | male |
| Fan Dong | Chairman of Board of Directors & GM | — | male |
| Feng Li | VP & Non-Independent Director | — | male |
| Rui Wang | General Manager | — | male |
| Xian Min Tang | VP & Director | — | female |
| Xueyun Liao | Director & Financial Director | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300529.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
